How have EOLS and MNPR total returns compared?

Over the past 5 years, EOLS delivered 0.46% and MNPR delivered 27.38% annualized total return. Past performance doesn't predict future results.

Evolus, Inc. (EOLS) vs Monopar Therapeutics Inc. (MNPR)

A side-by-side comparison of Evolus, Inc. and Monopar Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

EOLS

Evolus, Inc.

$490M

$7.45HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT

MNPR

Monopar Therapeutics Inc.

$523M

$78.10HealthcareDelayed quote: Oct 6, 2026, 12:54 PM EDT

Total return — EOLS vs MNPR

growth of $100 · dividends reinvested · last 7y

EOLS -37.8% (-6.6%/yr)MNPR -40.9% (-7.2%/yr)EOLS compounded faster over this window

EOLS MNPR

EOLS vs MNPR: by the numbers

•MNPR is the larger company ($523M vs $490M market cap).
•Both run net losses; MNPR's is the smaller (0.00% vs -10.85% net margin).

Metrics side by side

Valuation

Metric	EOLS	MNPR
P/S ratio	1.55	N/A
P/B ratio	N/A	4.00

Profitability

Metric	EOLS	MNPR
Gross margin	66.25%	0.00%
Operating margin	-7.33%	0.00%
Net margin	-10.85%	0.00%
ROE	N/A	-13.64%
ROIC	-15.54%	-16.89%

Growth (annualized)

Metric	EOLS	MNPR
Revenue CAGR (5Y)	32.82%	N/A
Total return CAGR (5Y)	0.46%	27.38%

Frequently asked

How have EOLS and MNPR total returns compared?: Over the past 5 years, EOLS delivered 0.46% and MNPR delivered 27.38% annualized total return. Past performance doesn't predict future results.

Go deeper

Full EOLS analysis Full MNPR analysis Interactive comparison tool

Dig into the metrics

Evolus ROE Monopar Therapeutics ROE Evolus operating margin Monopar Therapeutics operating margin Evolus revenue growth Monopar Therapeutics revenue growth Evolus free cash flow Monopar Therapeutics free cash flow

Evolus & Monopar Therapeutics appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.